Images List Premium Download Classic

Therapeutical

Therapeutical-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity
Angion Biomedica Corp.
January 11, 2018 - N°20180009793

The present invention provides compositions and formulations of compounds having formula (i) and pharmaceutically acceptable derivatives thereof, wherein p, r1, r2 and b are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of injuries, conditions or diseases in which ...
Novel formulation of metaxalone
Iceutica Pty Ltd.
January 11, 2018 - N°20180009769

The present invention relates to methods for producing particles of metaxalone using dry milling processes as well as compositions comprising metaxalone, medicaments produced using metaxalone in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of metaxalone administered by way of said medicaments.
Methods of treating psoriatic arthritis using il-17 antagonists
Novartis Ag
January 11, 2018 - N°20180008706

The disclosure relates to novel regimens for treating an inflammatory arthritis, e. G., psoriatic arthritis, which employ a therapeutically effective amount of an il-17 antagonist, e. G., il-17 binding molecule (e. G., il-17 antibody or antigen binding fragment thereof, e. G., secukinumab) or il-17 receptor binding molecule (e. G., il-17 antibody or antigen binding fragment thereof).
Therapeutical Patent Pack
Download 734+ patent application PDFs
Therapeutical Patent Applications
Download 734+ Therapeutical-related PDFs
For professional research & prior art discovery
inventor
  • 734+ full patent PDF documents of Therapeutical-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Treatment of right ventricular dysfunction due to pressure overload
Ottawa Hospital Research Institute
January 11, 2018 - N°20180008673

A method is disclosed for inducing right ventricular (rv) adaptive remodeling in a patient suffering from pulmonary hypertension (ph) due to pressure overload comprising administering a therapeutically effective amount of a carditrophin-1 polypeptide, recombinant protein or a polynucleotide encoding ct-1 polypeptide or full-length protein.
Compositions and methods for preventing or treating pulmonary hypertension
The Regents Of The University Of Colorado, A Body Corporate
January 11, 2018 - N°20180008662

The present invention provides a method of treating and/or preventing pulmonary hypertension in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a bioactive peptide preparation derived from at least one botanical source.
Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof
Syndevrx, Inc.
January 11, 2018 - N°20180008630

One aspect of the invention provides polymer conjugated metap2 inhibitors. While not being bound by any particular theory, it is believed that coupling the metap2 inhibitory core via the linkers described herein provides compounds with superior efficacy to the parent small molecules and superior pharmacokinetic profiles. In one aspect of the invention, the polymer conjugated metap2 inhibitors are useful in ...
Therapeutical Patent Pack
Download 734+ patent application PDFs
Therapeutical Patent Applications
Download 734+ Therapeutical-related PDFs
For professional research & prior art discovery
inventor
  • 734+ full patent PDF documents of Therapeutical-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Transdermal delivery system containing galantamine or salts thereof
Taho Pharmaceuticals Ltd.
January 11, 2018 - N°20180008612

Disclosed herein is a transdermal delivery system comprising galantamine or its salt as an active ingredient. Also provided are methods of delivering a therapeutically effective amount of galantamine to a subject for the treatment of a disease condition. The disease condition includes a neurological condition such as alzheimer's disease. Kits including the transdermal delivery system and methods of making such ...
Methods of treating binge eating disorder
Neurovance, Inc.
January 11, 2018 - N°20180008575

Provided is a method of treating binge eating disorder (bed) in a patient in need thereof comprising administering a therapeutically effective amount of (1r,5s)-1-(naphthalen-2-yl)-3-azabicyclo[3. 1. 0]hexane, in free or pharmaceutically acceptable salt form, to the patient.
Compositions and methods for the treatment of pervasive development disorders
Case Western Reserve University
January 11, 2018 - N°20180008559

A method of treating a pervasive development disorder in a subject includes administering to the subject a therapeutically effective amount of an nmdar antagonist, with an intermittent dosing regimen.
Use of two botanicals with complementary activities for improvement of skin
The Regents Of The University Of Michigan
January 11, 2018 - N°20180008557

A skin augmentation composition comprises a therapeutically effective amount of a combination of a gingerol and a curcumin and a cosmetically or pharmaceutically acceptable carrier. Methods for enhancing the repair of damaged skin and the prevention of developing wounds in a subject having damaged skin comprises administering to a portion of damaged skin, a composition comprising a therapeutically effective amount ...
Methods of treating retinal diseases
Cell Cure Neurosciences Ltd.
January 11, 2018 - N°20180008458

A method of treating a subject with dry-form age-related macular degeneration (amd) is disclosed. The method comprises administering into the subretina of the subject a therapeutically effective amount of a pharmaceutical composition comprising human rpe cells, wherein at least 95% of the cells thereof co-express premelanosome protein (pmel17) and cellular retinaldehyde binding protein (cralbp), wherein the trans-epithelial electrical resistance of the ...
Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
President And Fellows Of Harvard College
January 04, 2018 - N°20180002754

Disclosed herein are methods of treating cancer in a subject, and methods for inhibiting growth, migration and/or invasion of a cancer cell in the subject, comprising administering to the subject a therapeutically effective amount of an antibody or antigen binding fragment thereof that downmodulales fzd2. The antibody may specifically bind fzd2, and may promote internalization of the fzd2 receptor ...
Methods and compositions for treating malignant tumors associated with kras mutation
Nitto Denko Corporation
January 04, 2018 - N°20180002702

This invention provides methods and compositions for preventing, treating or ameliorating one or more symptoms of a malignant tumor, which may be associated with kras mutation in a mammal in need thereof, by administering to the mammal a therapeutically effective amount of a composition comprising one or more rnai molecules that are active in reducing expression of gst-π.
Therapeutical Patent Pack
Download 734+ patent application PDFs
Therapeutical Patent Applications
Download 734+ Therapeutical-related PDFs
For professional research & prior art discovery
inventor
  • 734+ full patent PDF documents of Therapeutical-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Tricyclic sulfones as ror gamma modulators
Technion Research & Development Foundation Limited
January 04, 2018 - N°20180002358

Or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating rorγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit ...
Hyaluronic acid-based gels including lidocaine
Allergan Industrie Sas
January 04, 2018 - N°20180000992

Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. The present hyaluronic acid-based compositions including lidocaine have an enhanced stability and cohesivity, relative to conventional ...
Stable pharmaceutical solution formulation of glp-1r antibody fusion protein
Gmax Biopharm Llc.
January 04, 2018 - N°20180000934

Disclosed is a stable pharmaceutical solution formulation of a glp-1r antibody fusion protein, comprising a therapeutically effective amount of the glp-1r antibody fusion protein, an amino acid, a surfactant and a buffer system. The final concentration of the amino acid is 1-500 mm, the final concentration of the surfactant is 0. 01%-0. 5%, and the ph value of the stable ...
Prevention and treatment of itch with an mrgpr antagonist
The General Hospital Corporation
January 04, 2018 - N°20180000886

Embodiments described herein relates to compositions and methods of preventing and/or treating itch in a subject using a therapeutically effective amount of a mrg receptor antagonist. E. G., a tripeptide qwf. In one embodiment, the itch is a non-histamine mediated itch.
Method of treating ischemic heart disease
King Abdulaziz University
January 04, 2018 - N°20180000883

A method of treating ischemic heart disease can include administering a therapeutically effective amount of a composition including date seed nanoparticles to a subject in need thereof. Exemplary suitable dosage forms can include tablet, gel, paste, and suspension. The therapeutically effective amount of the composition including date seed nanoparticles can be about 2. 0 mg/kg to about 2. 5 mg/kg.
Bacillus coagulans mtcc 5856 for the management of major depressive disorder
King Abdulaziz University
January 04, 2018 - N°20180000873

The present invention discloses the use of probiotics for therapeutic management of major depressive disorder (mdd). Specifically, the invention discloses the method of therapeutically managing mdd in mammals with irritable bowel syndrome using probiotic strain bacillus coagulans mtcc 5856.
Method of treating neurological conditions with oleandrin
Phoenix Biotechnology, Inc.
January 04, 2018 - N°20180000852

A method of treating neurological condition in a subject by administration of a cardiac glycoside is provided. Alzheimer's disease, huntington's disease or stroke are treated by administering a therapeutically effective amount of cardiac glycoside, and optionally triterpene(s), to a subject. The cardiac glycoside can be present in a dosage form.
Combination therapy
Dimerix Bioscience Pty Ltd
January 04, 2018 - N°20180000826

The invention relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof, and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof; and (b) at least ...
Loading